NCT05227118View on ClinicalTrials.gov

MK-8189 Safety and Tolerability in Participants With Alzheimer's Disease With or Without Symptoms of Agitation-Aggression and/or Psychosis (MK-8189-017)

PHASE1CompletedINTERVENTIONAL
Enrollment

29

Participants

Timeline

Start Date

July 1, 2022

Primary Completion Date

January 10, 2023

Study Completion Date

January 10, 2023

Conditions
Alzheimer's Disease
Interventions
DRUG

MK-8189

MK-8189 administered orally once a day (QD) at a titration via tablet in 4 mg and 12 mg dose strengths

DRUG

Placebo

MK-8189 matching placebo administered orally QD

Trial Locations (8)

10314

Richmond Behavioral Associates ( Site 0003), Staten Island

30030

iResearch Atlanta ( Site 0009), Decatur

30331

Atlanta Center for Medical Research ( Site 0004), Atlanta

33009

Velocity Clinical Research, Hallandale Beach ( Site 0001), Hallandale

33173

Well Pharma Medical Research, Corp. ( Site 0006), Miami

33189

Top Medical Research ( Site 0005), Cutler Bay

92705

CITrials ( Site 0007), Santa Ana

08540

Global Medical Institutes LLC; Princeton Medical Institute ( Site 0008), Princeton

All Listed Sponsors
lead

Merck Sharp & Dohme LLC

INDUSTRY